GlassScriptPhysician profile
Seong R Cho
NPI 1811082886
$10,588.75
in general payments reported to CMS, 2019-2025
51 companies · $1,749 in 2025
The $1,749 reported for 2025 was more than what 89% of Radiation Oncology providers received nationally (typical 2025 total: $172).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $907 · 2020: $863 · 2021: $1,134 · 2022: $1,725 · 2023: $1,950 · 2024: $2,261 · 2025: $1,749.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,960.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,959.51 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,928.93 | 2019-2025 | |
| Janssen Biotech, INC. | $1,392.50 | 2019-2025 | Darzalex, Erleada, Tecvayli |
| Merck Sharp & Dohme LLC | $1,072.84 | 2019-2025 | Keytruda, Lynparza, Welireg |
| Astrazeneca Pharmaceuticals LP | $814.89 | 2020-2025 | Imfinzi, Lynparza, Enhertu |
| Abbvie INC. | $513.72 | 2021-2025 | Venclexta |
| Bayer Healthcare Pharmaceuticals INC. | $352.35 | 2019-2025 | |
| Daiichi Sankyo INC. | $347.51 | 2019-2025 | Injectafer, Enhertu |
| Lilly USA, LLC | $340.61 | 2019-2025 | Verzenio, Jaypirca, Retevmo |
| Regeneron Healthcare Solutions, INC. | $325.65 | 2021-2025 | Libtayo |
| Eisai INC. | $325.17 | 2020-2024 | |
| Incyte Corporation | $264.35 | 2019-2025 | Jakafi, Monjuvi, Pemazyre |
| Genentech USA, INC. | $179.69 | 2019-2025 | Tecentriq, Rozlytrek, Alecensa |
| Jazz Pharmaceuticals INC. | $168.48 | 2020-2025 | Zepzelca |
| Emd Serono, INC. | $165.04 | 2019-2025 | Bavencio |
| Celgene Corporation | $157.66 | 2019-2020 |
Show all 51 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Seong Cho listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.